TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31554423
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter)
Study: 31553203
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose, 75 mg daily thereafter)
Study: 27586537
Drug: Glycopyrrolate (GP)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (GP) MDI 18, 9, 4.6, and 2.4 μg, twice daily (BID)
Study: 27586537
Drug: Glycopyrrolate (GP)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (GP) MDI 18 μg, twice daily (BID)
Study: 27586537
Drug: Placebo MDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI, twice daily (BID)
Study: 27586537
Drug: Open-label tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label tiotropium dry powder inhaler 18 μg, once daily (QD)
Study: 23925361
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg every 4 weeks
Study: 19297346
Drug: Methotrexate starting
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate starting at 7.5 mg/week titrated to 20 mg/week
Study: 17491221
Drug: Coronary calcification
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary calcification (CC)
Study: 17491221
Drug: Severity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity of CC and severity of aortic calcification
Study: 16053368
Drug: 2.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine gel
Study: 12052273
Drug: Intracoronary stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary stenting and intravenous glycoprotein IIb/IIIa antagonists
Study: 10201667
Drug: 10 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 U/kg of unfractionated heparin
Study: 10201667
Drug: 20 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 U/kg of unfractionated heparin
Study: 7601403
Drug: Therapeutic paracentesis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic paracentesis plus intravenous albumin
Study: 2118858
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) 3.75 mg
Study: 28899844
Drug: Lipid ibuprofen
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid ibuprofen 1200 mg/day
Study: 28899844
Drug: Soft-gel ibuprofen
Normalized name: ibuprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-gel ibuprofen 1200 mg/day
Study: 28899844
Drug: Soft-gel ibuprofen
Normalized name: ibuprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-gel ibuprofen 2400 mg/day
Study: 2782362
Drug: Sublingual and
Normalized name: Buprenorphine and Naloxone Sublingual Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual and oral nifedipine
Study: 2782362
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral ritodrine
Study: 943354
Drug: Methandrostenolone at
Normalized name: methandrostenolone
DrugBank: Metandienone (DB13586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methandrostenolone at a dose of 25 mg im.m. per day for the first ten days from the beginning of symptoms
Study: 31060939
Drug: aPRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPRP treatment group
Study: 28919143
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate 50 μg twice daily (BID)
Study: 28919143
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once daily (OD)
Study: 21692285
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Naproxen Sunstained Release Capsule, 2 tablets taken 30 min after operation and then 2 tablets a day before dressing change)
Study: 19889206
Drug: TachoSil patches
Normalized name: fibrinogen / thrombin Medicated Patch [TachoSil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil patches
Study: 11354448
Drug: 4.5 ml
Normalized name: 4.5 ML Triferic 1.5 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 ml polylactic acid (PLA) bioabsorbable syndesmotic screw
Study: 9216530
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream application
Study: 9216530
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream application followed by infiltration of 1% lidocaine
Study: 2445118
Drug: Mexiletine 200
Normalized name: mexiletine 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 200 mg t.i.d.
Study: 2445118
Drug: Mexiletine perlongettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine perlongettes 360 mg b.i.d.
Study: 29526693
Drug: Commercial non-carbonated
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial non-carbonated LCS lemonade (330 ml) consumed with meals
Study: 29526693
Drug: 660 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 ml LCS lemonade daily (habituation group)
Study: 29526693
Drug: 660 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 ml water (control group)
Study: 20623311
Drug: Joint lavage
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint lavage in combination with triamcinolone hexacetonide (TH) intra-articular injection
Study: 20623311
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (TH) intra-articular injection
Study: 20623311
Drug: Joint lavage
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint lavage in combination with TH
Study: 18926392
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with SCA (group 2: 12 patients on chronic transfusion therapy)
Study: 12837672
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (250 mg/day - 1,500 mg/day; mean: 851 mg/day)
Study: 10784625
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine intensification
Study: 9309990
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation
Study: 3159530
Drug: Ciprofloxacin 25
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 25 mg
Study: 3159530
Drug: Ciprofloxacin 50
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 50 mg
Study: 3159530
Drug: Ciprofloxacin 75
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 75 mg
Study: 31658113
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine lozenge
Study: 27430374
Drug: Artesunate-mefloquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (25 mg artesunate and 55 mg mefloquine) once a day for 3 days
Study: 27430374
Drug: Artemether-lumefantrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine) twice a day for 3 days
Study: 20421332
Drug: rhGH (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (both doses)
Study: 19077190
Drug: Exercise on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise on Prescription program with weekly exercise sessions for 20 weeks
Study: 12828743
Drug: Synchronous balneo-phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synchronous balneo-phototherapy (simultaneous application of narrowband ultraviolet B and bathing in 10% Dead Sea salt solution)
Study: 10494182
Drug: Various methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various methods of immunotherapy (interleukin‐2, Linomid, mixed hemopoietic cell transplantation)
Study: 2069877
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose regimen of tamoxifen (160 mg for two days followed by 40 mg/day)
Study: 2069877
Drug: Conventional schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional schedule of tamoxifen (40 mg/day)
Study: 31923762
Drug: TRAIL/Apo2L monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAIL/Apo2L monotherapy
Study: 23667467
Drug: Estrogen combined
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen combined with medroxyprogesterone acetate therapy
Study: 19894006
Drug: Functional magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional magnetic stimulation (20-min stimulation session twice daily for 3 weeks)
Study: 15530138
Drug: Induction morphine
Normalized name: morphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction morphine
Study: 14665865
Drug: 19 intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 1 year (group 1)
Study: 14665865
Drug: 9 intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 3 months (group 2)
Study: 10403729
Drug: Empirical eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empirical eradication therapy
Study: 7029236
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (SV)
Study: 10438047
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three vaccines
Study: 30335525
Drug: in vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: in vivo exposure therapy (iVET)
Study: 30335525
Drug: virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: virtual reality exposure therapy (VRET)
Study: 30335525
Drug: augmented reality
Approvals — FDA: no, EMA: no, PMDA: no
Description: augmented reality exposure therapy (ARET)
Study: 19752552
Drug: terutroban 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: terutroban 10 mg/day
Study: 19752552
Drug: terutroban 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: terutroban 10 mg/day + aspirin 300 mg/day
Study: 19752552
Drug: clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel 75 mg/day + aspirin 300 mg/day
Study: 19752552
Drug: aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 300 mg/day
Study: 15134983
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg once daily plus standard care
Study: 9506661
Drug: Cholestyramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine treatment
Study: 26881996
Drug: Alveolar recruitment
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alveolar recruitment manoeuvres (ARM) and surfactant administration every 8 hours for 3 days
Study: 31343761
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment only
Study: 23316699
Drug: TAP50 (tapentadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP50 (tapentadol hydrochloride extended-release 50 mg)
Study: 23316699
Drug: TAP250 (tapentadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP250 (tapentadol hydrochloride 250 mg)
Study: 23316699
Drug: OXY40 (OxyContin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXY40 (OxyContin® 40 mg)
Study: 20200310
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (2 units/h with 100 ml of 5% dextrose/h for 4 h)
Study: 20200310
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion (100 ml of 5% dextrose/h for 4 h)
Study: 20200310
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (100 ml of saline/h for 4 h)
Study: 12173011
Drug: Normal whole-body
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal whole-body insulin sensitivity
Study: 12173011
Drug: Low whole-body
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low whole-body insulin sensitivity
Study: 7762775
Drug: Thiopentone (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4-5 mg/kg) and enflurane
Study: 7762775
Drug: Propofol (2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2-2.5 mg/kg) infusion
Study: 2324538
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza B reassortant virus vaccine (10^7.5 TCID50)
Study: 30962095
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine 100 μg
Study: 30962095
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine 200 μg
Study: 30962095
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine 100 μg (day regimen)
Study: 30962095
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine 200 μg (month regimen)
Study: 26681191
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (Duraphat®) plus treatment as usual
Study: 21477658
Drug: 7-day buprenorphine
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day buprenorphine patches plus oral paracetamol (5-25 μg/h buprenorphine patches plus 1000 mg oral paracetamol q.i.d.; n=110)
Study: 21477658
Drug: Co-codamol tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-codamol tablets (two 8/500-two 30/500 mg tablets q.i.d.; n=110)
Study: 17581601
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg (L)
Study: 17581601
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg (E)
Study: 17581601
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg plus Enalapril 20 mg (L/E)
Study: 10200006
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg daily)
Study: 12487225
Drug: Oxatomide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (1 mg/kg, twice daily)
Study: 12487225
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg, twice daily)
Study: 9915661
Drug: Niaspan (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan (extended-release niacin) at a dosage of 2,000 mg/day
Study: 9915661
Drug: Niaspan (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan (extended-release niacin)
Study: 29127425
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (804 mg/d)
Study: 29127425
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid (600 mg/d)
Study: 27124606
Drug: Curcumin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1000 mg/d in 2 divided doses)
Study: 17241861
Drug: Tetomilast 25
Normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetomilast 25 mg
Study: 17241861
Drug: Tetomilast 50
Normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetomilast 50 mg
Study: 12081827
Drug: Etomoxir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomoxir (600 mg total over 5 doses)
Study: 7847595
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg daily)
Study: 2225476
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg p.o.)
Study: 2225476
Drug: Pyridostigmine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine plus lipid-heparin plus GHRH
Study: 27083315
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.3 mg administered preoperatively via lumbar puncture
Study: 27083315
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository (DS) 50 mg administered at the end of surgery
Study: 21875244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of decision advice with uncertainty estimates
Study: 18359604
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=78): Patients received usual customary care during weekly medical visits.
Study: 14653835
Drug: Lafutidine 20
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 20 mg
Study: 9592319
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol Acetate (MA) 160 mg/day orally for two weeks
Study: 6628224
Drug: Chlorophyllin 100
Normalized name: chlorophyllin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyllin 100 mg/d for two weeks
Study: 31343402
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (200 mg once or twice a day) for 1 year
Study: 29520729
Drug: Velpatasvir 100
Normalized name: velpatasvir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velpatasvir 100 mg single dose
Study: 19172226
Drug: Low-frequency exerciser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency exerciser (LFE) - exercise training at least 30 min twice per week or less
Study: 17301265
Drug: Long-chain n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain n-3 fatty acids (quartiles) among men not on aspirin
Study: 17301265
Drug: Aspirin (randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (randomized assignment)
Study: 7650231
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg bid
Study: 7650231
Drug: Venlafaxine 50
Normalized name: venlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 50 mg tid
Study: 30817999
Drug: HER2-peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2-peptide vaccine nelipepimut-S + GM-CSF with trastuzumab
Study: 28938963
Drug: Allogeneic human
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic human mesenchymal stem cell injection
Study: 28938963
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical care (no injection)
Study: 24179108
Drug: Simple hand
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [Clean Simple Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple hand hygiene plus antiseptic hand hygiene (water and glycerin soap for 1 minute followed by 70% ethyl alcohol gel)
Study: 24179108
Drug: Antiseptic hand
Normalized name: MCD Antiseptic Hand
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiseptic hand hygiene (70% ethyl alcohol gel until fully dry)
Study: 24179108
Drug: Gel-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-only group (intervention)
Study: 14717485
Drug: Healon (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healon (sodium hyaluronate) 0.05 ml injected into anterior chamber; n = 20
Study: 14717485
Drug: Control (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (balanced salt solution) 0.05 ml injected into anterior chamber; n = 18
Study: 10390129
Drug: Etofibrate treatment
Normalized name: etofibrate
DrugBank: Etofibrate (DB08983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofibrate treatment for 6 weeks
Study: 1381626
Drug: G-CSF (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (230 micrograms/m2 daily subcutaneous)
Study: 1381626
Drug: Control (VAPEC-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (VAPEC-B chemotherapy alone)
Study: 11314884
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg amoxicillin plus 250 mg metronidazole every 8 hours for 7 days
Study: 11314884
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets every 8 hours for 7 days
Study: 11314884
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (antibiotics) vs. Placebo group
Study: 9041216
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum cardiac troponin T (cTnT) concentrations greater than 0.20 micrograms/L at baseline
Study: 9041216
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum creatine kinase MB (CK‐MB) greater than 5.0 micrograms/L at baseline
Study: 9041216
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum cardiac troponin I (cTnI) greater than 0.8 micrograms/L at baseline